Detection of K‑ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study
- Xiaoguang Wang
- Jingshuai Wang
- Fei Chen
- Zhengxiang Zhong
- Lifeng Qi
Published online on: October 24, 2017
The present study aimed to investigate the feasibility and effectiveness of detecting K‑ras mutation by using magnetic nanoparticles in fecal samples of patients with pancreatic cancer at different stages. The novel methodology of K‑ras mutation detection was compared to the existing methodology of cancer antigen (CA)19‑9 examination. Patients with pancreatic cancer (n=88), pancreatic benign diseases who displayed chronic pancreatitis (n=35), pancreatic mucinous cyst neoplasms (n=10) and pancreatic serous cyst (n=9) admitted to the Department of Surgery, Jiaxing Second Hospital were enrolled in the present study. Fecal samples were collected from all patients, DNA was extracted and magnetic nanoprobe was then used to detect K‑ras mutation. The results obtained using the novel magnetic nanoprobe detection technique showed a K‑ras mutation rate of 81.8% (72/88) in the patients with pancreatic cancer and 18.5% (10/54) in patients with pancreatic benign diseases. In patients with pancreatic cancer, the K‑ras mutation rate was comparable in stages I + IIA and IIB + III + IV (78.9 vs. 84.0%; P>0.05). The sensitivity and specificity of K‑ras mutation for detection of pancreatic cancer was 81.8 and 81.5%, respectively. Sixty‑eight pancreatic cancer patients had >37 U/ml CA99 with a sensitivity and specificity for pancreatic cancer detection of 77.3 and 77.8%, which was not significantly lower than detection by the fecal K‑ras mutations (P>0.05). Combinational detection of fecal K‑ras mutations and serum CA19‑9 significantly increased the sensitivity regarding pancreatic cancer detection to 97.7% (P<0.05), while the specificity was not enhanced (80.9%; P>0.05) compared with fecal K‑ras mutations or CA19‑9 alone. The findings showed that the magnetic nanoprobe is able to detect fecal K‑ras mutations in different stages of pancreatic cancer, with comparable sensitivity and specificity to CA19‑9 examination for differentiating pancreatic cancer. Furthermore, combined detection of CA19‑9 and K‑ras mutations has enhanced sensitivity compared with CA19‑9 alone.